IMNR Biotechperle - 500 Beiträge pro Seite

[Mick1968]

The Immune Response Corporation Presenting at the RodmanThe Immune Response Corporation (OTCBB: IMNR)


IMNR has an impressive and serious team because they are doing impressive and serious work. This week we linked you to the presentation made at the Rodman & Renshaw Conference in New York. This presentation was made by Joseph O\'Neill, M.D. Here are some bio\'s of the powerhouse that is IMNR. http://www.wsw.com/webcast/rrshq10/imnr/

Joseph F. O’Neill, M.D. – President, Chief Executive Officer and Director
Dr. O’Neill joined IMNR in October 2005. Most recently, Dr. O’Neill was the Deputy Coordinator and Chief Medical Officer in the Office of the U.S. Global AIDS Coordinator, Department of State from August 2003 to August 2005. Prior to joining the State Department, Dr. O’Neill served as the Director of the White House Office of National AIDS Policy from July 2002 to August 2003. Prior to his White House appointment, he served as Acting Director of the Office of HIV/AIDS Policy in the Department of Health and Human Services from 2001 to July 2002. From 1997 to the end of 2001, Dr. O’Neill served as Associate Administrator for HIV/AIDS in the Health Resources and Services Administration’s HIV/AIDS Bureau. In addition, he serves on a number of advisory boards including the Robert Wood Johnson Foundation’s Promoting Excellence in End of Life Care program and the Brazilian Association for Palliative Care. Dr. O’Neill is a graduate of the School of Medicine of the University of California at San Francisco and holds degrees in business administration, public health, health and medical sciences from the University of California at Berkeley. He is board certified in internal medicine.

Michael K. Green – Chief Operating Officer and Chief Financial Officer
Mr. Green joined IMNR in October 2003, bringing over 25 years of extensive finance, business and accounting experience in various technology industries in both the United States and Australia. Mr. Green was promoted from Vice President, Finance to Chief Operating Officer on October 31, 2005, while retaining his Chief Financial Officer position. Mr. Green served as Senior Vice President and Chief Financial Officer of Synbiotics Corporation, a publicly traded animal health company, from May 1991 to September 2002 and as Chief Financial Officer of Immunopharmaceutics Inc., a human pharmaceutical company, from May 1991 to October 1993, where he was responsible for all finance, accounting, administrative, human resource and MIS matters. Before that Mr. Green spent 13 years with Price Waterhouse in various offices in the United States and Australia where he is a C.P.A. and a Chartered Accountant. Mr. Green co-authored the Price Waterhouse guidebook titled “Taking Your Company Public,” and the Price Waterhouse lecture series titled “Initial Public Offerings for Smaller Businesses.” Mr. Green holds a Bachelor of Business Studies degree from the New South Wales Institute of Technology in Sydney, Australia.

Georgia Theofan, Ph.D. – Vice President, Clinical Development
Dr. Theofan was appointed to the position of Vice President, Clinical Development in January 2003. Dr. Theofan has been with IMNR since November 1995, and has more than 17 years of experience in the biotechnology industry. Since joining IMNR, Dr. Theofan has been responsible for managing the operations of clinical trials in HIV, as well as cancer and autoimmune disease. She has over 40 publications in peer-reviewed scientific journals and is a co-inventor on nine patents. Dr. Theofan received a Ph.D. in Biology from the University of Notre Dame, and a Bachelor’s Degree in Biology from New York University. She also served as a post doctoral fellow at the University of Rochester in New York, and the University of California at both the Riverside and San Diego campuses.

Peter Lowry – Vice President, Manufacturing
Mr. Lowry was promoted to Vice President, Manufacturing in March 2006, and is currently responsible for all manufacturing and quality operations at the King of Prussia, Pennsylvania facility. Mr. Lowry joined IMNR in June 1995, and has over 15 years experience in biopharmaceutical research, bioprocess development, and large scale GMP manufacturing. He served as Executive Director, Manufacturing at the Pennsylvania facility from April 2002 to August 2004. From 1995 to April 2002, he headed quality control operations at both the Pennsylvania and California facilities. From April 2002 to August 2004, Mr. Lowry served as Senior Director, Operations, responsible for the manufacturing of all clinical trial products in support of IMNR’s HIV program. He currently serves on the Biotechnology Program Advisory Committee of Montgomery College. Prior to joining IMNR, Mr. Lowry was head of Viral Biochemistry at Advanced Biotechnologies Inc. Mr. Lowry holds a bachelor’s degree in Biochemistry from Rutgers College.

Robert E. Knowling, Jr. – Chairman of the Board
Mr. Knowling joined the Board as Chairman in February 2005. Mr. Knowling served as vice president of Network Operations and reported directly to the chairman of Ameritech Corporation from 1994 to 1996. He joined US WEST in March 1996 as vice president of Network Operations and in 1997 became EVP of Operations & Technology. He joined Covad Communications, a provider of Digital Subscriber Line (DSL) services to homes and small business customers, in July 1998 as chairman, president and chief executive officer. He joined the New York City Department of Education in January 2003 as Chief Executive Officer of their Leadership Academy. In April 2005, Mr. Knowling took over the position of chief executive officer at Vercuity Solutions, Inc., the largest, most experienced supplier of Telecom Expense Management services. He serves on the board of directors for Ariba, Inc. and Heidrick & Struggles International, Inc. He is also a member of the advisory boards for Ontologent, Inc.; Northwestern University’s Kellogg Graduate School of Management; and the University of Michigan Graduate School of Business. Mr. Knowling earned a Bachelor of Arts degree from Wabash College and a Master of Business Administration degree from Northwestern University’s Kellogg Graduate School of Business.

IMNR has created for its benefit and support a reservoir of talent that is active in the biotech industry and in their particular field be it HIF or MS.

Link here for:

* Board of Directors
http://www.imnr.com/corp/corporate_bod.htm

* HIV Scientific Advisory Board
http://www.imnr.com/corp/corporate_sab_hiv.htm

* MS Advisory Board
http://www.imnr.com/corp/corporate_sab_ms.htm


Source:
Immune Response Corp. (The)

[Mick1968]

[Mick1968]

2 Sehr heiße Eisen in der 2. Klinischen Phase NeuroVax gegen MS und IR103 gegen HIV.

[Mick1968]

Erste richtige NEWS seit Monaten


SmallCap Sentinel: The Biotech Road of Rags to Riches
IRVINE, Calif., Nov. 9, 2006 (PRIMEZONE) -- An investor-oriented analysis of Immune Response Corp. (OTCBB:IMNR) is now available at SmallCapNetwork.net. The report reveals the potential opportunity found in identifying low-priced biotech stocks based on technology and timing.

The report also highlights the rewarding returns experienced by investors of Amgen, Inc. (Nasdaq:AMGN) and Teva Pharmaceutical (Nasdaq:TEVA) during their early stages of corporate development.

To view the report in its entirety, please visit: http://www.smallcapdigest.net/archive/listserv/20061108-1.ht…

Access to the information is free of charge. Investors in this sector or small caps in general are invited and encouraged to register for Future briefings and analysis on emergent small and micro cap companies by signing-up at the SmallCap Network\'s member page: http://www.smallcapnetwork.net/opt.php" target="_blank" rel="nofollow ugc noopener">http://www.smallcapnetwork.net/opt.php

About SmallCap Network:

The SmallCap Network, a leading financial publisher, provides equity trading ideas and market guidance through its website http://www.smallcapnetwork.net and free email newsletter, the SmallCap Digest.

The e-newsletter and site focuses on potential up-and-coming small and micro-cap stocks. The SmallCap Network follows the progress of potentially undervalued companies, which may have not yet attracted a major Wall Street following. Third-party research has shown that over time smaller companies, like the ones highlighted by the Small Network, tend to outperform large-cap stocks often featured by most other major media outlets.

The SmallCap Network issues bullish/bearish market calls, and specific stock and option trades, in addition to its profiled companies. The site\'s trading ideas and guidance have provided outstanding results for readers since inception in 2001. The SmallCap Network also features unique educational content, timely market-related articles and an interactive blog.

Learn more about the SmallCap Network by visiting: http://www.smallcapnetwork.net.

[Mick1968]

Bei der Suche nach der Anzahl der leerverkauften Stücke "Short Interest" auf NASDAQ kommt: Short Interest Not available for IMNR .
Bitteschön, der Link:
http://www.nasdaq.com/asp/quotes_full.asp?mode=&kind=shortin…

Und bei Yahoo Finace sieht das so aus:
http://finance.yahoo.com/q/bs?s=IMNR.OB